ArticleNature medicine2017
A chikungunya fever vaccine utilizing an insect-specific virus platform.
Article in Nature medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 2 syntheses or guidelines pooled it, 165 citations in OpenAlex.
- Visualized analysis of core themes and emerging frontiers in global chikungunya virus studies.Frontiers in microbiology · 2025Pooled it
- The neurological complications of chikungunya virus: A systematic review.Reviews in medical virology · 2018Pooled it
- Live-Attenuated Rift Valley Fever Virus Vaccination Leads to Durable, Protective Immunity Independent of Sex in C57BL/6 Mice.The Journal of infectious diseases · 2026Article
- Chikungunya in 2025: Comprehensive Insights into Virology, Diagnostics, Vaccines, and Antiviral Therapies.Viruses · 2026Review
- Suspension cultivation of mosquito cell lines for the production of the mosquito-borne flavivirus Usutu virus in a stirred-tank bioreactor.Scientific reports · 2026Article
- Comment on: A single dose recombinant AAV based CHIKV vaccine elicits robust and durable protective antibody responses in mice.PLoS neglected tropical diseases · 2025Article
- A Review of the Biology of Chikungunya Virus Highlighting the Development of Current Novel Therapeutic and Prevention Approaches.Pathogens (Basel, Switzerland) · 2025Review
- γδ T Cells Mediate Protective Immunity Following Vaccination with an Insect-Based Chikungunya Fever Vaccine in Mice.Pathogens (Basel, Switzerland) · 2025Article
- Insect-Specific Flaviviruses Have Potential Applications as a Scaffold for Pathogenic Flavivirus Vaccines.Vaccines · 2025Review
- Review
- A replicon-based COVID-19 vaccine candidate delivered by tobacco mosaic virus-like particles.Vaccine · 2025Article
- The Application of DNA Viruses to Biotechnology.Viruses · 2025Review
- Serum-Free Suspension Culture of theViruses · 2025Article
- Insect-specific virus platforms for arbovirus vaccine development.Frontiers in immunology · 2025Review
- A safe insect-based chikungunya fever vaccine affords rapid and durable protection in cynomolgus macaques.NPJ vaccines · 2024Article
- Attenuated Getah virus confers protection against multiple arthritogenic alphaviruses.PLoS pathogens · 2024Article
- Humoral and T-cell-mediated responses to an insect-specific flavivirus-based Zika virus vaccine candidate.PLoS pathogens · 2024Article
- Synthetic recovery of Yada Yada virus expands insect-specific alphavirus knowledge and facilitates production of chimeric viruses.Npj viruses · 2024Article
- Article
- Ly6CCell reports · 2024Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
Traditionally, vaccine development involves tradeoffs between immunogenicity and safety. Live-attenuated vaccines typically offer rapid and durable immunity but have reduced safety when compared to inactivated vaccines. In contrast, the inability of inactivated vaccines to replicate enhances safety at the expense of immunogenicity, often necessitating multiple doses and boosters. To overcome these tradeoffs, we developed the insect-specific alphavirus, Eilat virus (EILV), as a vaccine platform. To address the chikungunya fever (CHIKF) pandemic, we used an EILV cDNA clone to design a chimeric virus containing the chikungunya virus (CHIKV) structural proteins. The recombinant EILV/CHIKV was structurally identical at 10 Å to wild-type CHIKV, as determined by single-particle cryo-electron microscopy, and it mimicked the early stages of CHIKV replication in vertebrate cells from attachment and entry to viral RNA delivery. Yet the recombinant virus remained completely defective for productive replication, providing a high degree of safety. A single dose of EILV/CHIKV produced in mosquito cells elicited rapid (within 4 d) and long-lasting (>290 d) neutralizing antibodies that provided complete protection in two different mouse models. In nonhuman primates, EILV/CHIKV elicited rapid and robust immunity that protected against viremia and telemetrically monitored fever. Our EILV platform represents the first structurally native application of an insect-specific virus in preclinical vaccine development and highlights the potential application of such viruses in vaccinology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.